NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting...
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 30, 2025...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30,...
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of lifeRESEARCH TRIANGLE...
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing...
Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical developmentSOUTH...
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval...
Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan®...
Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median...
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless...
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of...
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“MediPharm” or the “Company”), a...
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate...
SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced...
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused...
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized...
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences:...
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform...
JOHNSON CITY, Tenn., May 29, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement...